Robert G Maki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7110627/publications.pdf

Version: 2024-02-01

457 papers	45,923 citations	2565 99 h-index	2289 206 g-index
478 all docs	478 docs citations	478 times ranked	35366 citing authors

#	Article	IF	Citations
1	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. Journal of Clinical Oncology, 2022, 40, 1291-1300.	0.8	24
2	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. Cancer Immunology, Immunotherapy, 2022, 71, 807-818.	2.0	8
3	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. JAMA Oncology, 2022, 8, 740.	3.4	12
4	Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clinical Cancer Research, 2022, , .	3.2	0
5	Impact of Intraoperative Molecular Imaging after Fluorescent-Guided Pulmonary Metastasectomy for Sarcoma. Journal of the American College of Surgeons, 2022, 234, 748-758.	0.2	9
6	SELNET clinical practice guidelines for bone sarcoma. Critical Reviews in Oncology/Hematology, 2022, 174, 103685.	2.0	12
7	Ewing sarcoma and related <scp>FET</scp> family translocationâ€associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes and Cancer, 2022, 61, 509-517.	1.5	5
8	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations inCTNNB1orAPC: A Multi-institutional Retrospective Study. Clinical Cancer Research, 2022, 28, 4092-4104.	3.2	8
9	MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.. Journal of Clinical Oncology, 2022, 40, TPS11589-TPS11589.	0.8	2
10	Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. Cancer Research, 2022, 82, CT235-CT235.	0.4	0
11	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	5.8	51
12	A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1.. Journal of Clinical Oncology, 2022, 40, TPS11586-TPS11586.	0.8	0
13	Definitive Local Therapy Is Associated with Improved Survival in Metastatic Soft Tissue Sarcomas. Cancers, 2021, 13, 932.	1.7	3
14	Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. Sarcoma, 2021, 2021, 1-11.	0.7	1
15	A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.. Journal of Clinical Oncology, 2021, 39, TPS11583-TPS11583.	0.8	2
16	Surgical Management of Sarcoma Metastatic to Liver. Surgical Oncology Clinics of North America, 2021, 30, 57-67.	0.6	5
17	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer, 2020, 126, 98-104.	2.0	25
18	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6

#	Article	IF	Citations
19	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	0.6	103
20	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist, 2020, 25, e1655-e1662.	1.9	13
21	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncology, 2020, 16, 4289-4301.	1.1	12
22	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
23	Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. Clinical Cancer Research, 2020, 26, 3958-3968.	3.2	10
24	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. OncoImmunology, 2020, 9, 1747340.	2.1	101
25	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer, 2020, 127, 96-107.	1.3	243
26	Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. BMJ Case Reports, 2020, 13, e234363.	0.2	14
27	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	0.8	101
28	Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDCS], histiocytic sarcoma [HS]).. Journal of Clinical Oncology, 2020, 38, e23574-e23574.	0.8	2
29	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology, 2019, 32, 1772-1785.	2.9	61
30	Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma. BMJ Case Reports, 2019, 12, e227475.	0.2	16
31	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports, 2019, 9, 14551.	1.6	41
32	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer, 2019, 125, 4435-4441.	2.0	10
33	Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Annals of Oncology, 2019, 30, v683.	0.6	15
34	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 2019, 120, 132-139.	1.3	24
35	An IRAK1â€“PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	4.6	38
36	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 2019, 19, 593.	1.1	13

#	Article	IF	Citations
37	An unusual case of Kaposi sarcoma masquerading as cystitis in a kidney transplant recipient. Transplant Infectious Disease, 2019, 21, e13132.	0.7	6
38	Overall survival and histologyâ€specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer, 2019, 125, 2610-2620.	2.0	47
39	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British Journal of Cancer, 2019, 120, 1026-1032.	2.9	33
40	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 877-886.	5.1	75
41	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAbâ€004) in metastatic softâ€tissue sarcomas. Cancer, 2019, 125, 2445-2454.	2.0	19
42	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology, 2019, 37, 1424-1431.	0.8	172
43	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. Journal of Bone and Joint Surgery - Series A, 2019, 101, 1309-1318.	1.4	30
44	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. Oncologist, 2019, 24, 857-863.	1.9	15
45	Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma. JAMA Oncology, 2019, 5, 254.	3.4	89
46	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. Journal of Clinical Oncology, 2019, 37, 11015-11015.	0.8	65
47	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), Â± cemiplimab in patients (pts) with advanced malignancies.. Journal of Clinical Oncology, 2019, 37, 2508-2508.	0.8	26
48	Abstract 2155: High-plex spatial profiling analysis of multidrug CIVO microdose studies in cancer patients. , 2019, , .		0
49	Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Oncology, 2018, 29, 857-871.	0.6	55
50	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 2018, 23, 62-70.	1.9	62
51	Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. Journal of Clinical Oncology, 2018, 36, 194-201.	0.8	38
52	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
53	Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. Journal of Clinical Oncology, 2018, 36, 210-216.	0.8	62
54	Sarcoma: The Merging of Science and Clinical Care. Journal of Clinical Oncology, 2018, 36, 99-100.	0.8	4

#	Article	IF	Citations
55	Sorafenib for Advanced and Refractory Desmoid Tumors. New England Journal of Medicine, 2018, 379, 2417-2428.	13.9	287
56	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor. JAMA Oncology, 2018, 4, e184060.	3.4	112
57	A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. Clinical Cancer Research, 2018, 24, 4968-4975.	3.2	12
58	<scp>TERT</scp> promoter mutations in solitary fibrous tumour. Histopathology, 2018, 73, 843-851.	1.6	47
59	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Annals of Oncology, 2018, 29, 1995-2002.	0.6	30
60	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. Journal of Clinical Oncology, 2018, 36, 11505-11505.	0.8	3
61	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. Journal of Clinical Oncology, 2018, 36, TPS11590-TPS11590.	0.8	1
62	A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21158-e21158.	0.8	0
63	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. Journal of Clinical Oncology, 2018, 36, e23570-e23570.	0.8	0
64	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. Journal of Clinical Oncology, 2018, 36, 11513-11513.	0.8	0
65	Evaluation and Management of Sarcomas. , 2018, , .		0
66	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. JAMA Oncology, 2017, 3, 944.	3.4	73
67	Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. European Journal of Cancer, 2017, 72, S155.	1.3	0
68	Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncology, 2017, 13, 13-21.	1.1	26
69	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1493-1501.	5.1	921
70	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Annals of Oncology, 2017, 28, 2595-2605.	0.6	229
71	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Modern Pathology, 2017, 30, 1433-1442.	2.9	261
72	Targeting sarcoma tumor-initiating cells through differentiation therapy. Stem Cell Research, 2017, 21, 117-123.	0.3	9

#	Article	IF	Citations
73	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	13.5	738
74	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology, 2017, 146, 531-537.	0.6	51
75	Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis. Annals of Oncology, 2017, 28, v529.	0.6	2
76	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. Journal of Clinical Oncology, 2017, 35, 3433-3439.	0.8	126
77	Title is missing!. , 2017, , .		8
78	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. Journal of Clinical Oncology, 2017, 35, 11001-11001.	0.8	26
79	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. Journal of Clinical Oncology, 2017, 35, 11005-11005.	0.8	30
80	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	0.8	32
81	Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.. Journal of Clinical Oncology, 2017, 35, 11009-11009.	0.8	8
82	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. Journal of Clinical Oncology, 2017, 35, TPS11081-TPS11081.	0.8	5
83	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. Journal of Clinical Oncology, 2017, 35, 60-60.	0.8	3
84	Title is missing!. , 2017, , .		3
85	Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate?. Journal of Clinical Oncology, 2017, 35, e22522-e22522.	0.8	0
86	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. Journal of Clinical Oncology, 2017, 35, e22516-e22516.	0.8	0
87	Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts). Annals of Oncology, 2016, 27, vii74.	0.6	1
88	Management of Soft Tissue Sarcoma. , 2016, , .		12
89	Fibrosarcoma and Its Variants. , 2016, , 203-219.		0
90	Mostly Benign/Rarely Metastasizing. , 2016, , 355-367.		0

#	Article	IF	Citations
91	Selected Benign Tumors. , 2016, , 369-386.		0
92	Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults. JAMA Oncology, 2016, 2, 941.	3.4	21
93	Perspectives for immunotherapy in endocrine cancer. Endocrine-Related Cancer, 2016, 23, R469-R484.	1.6	12
94	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncology, The, 2016, 17, 1261-1271.	5.1	161
95	Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. Gastroenterology Clinics of North America, 2016, 45, 477-486.	1.0	4
96	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of Clinical Oncology, 2016, 34, 3898-3905.	0.8	151
97	Patient-derived xenografts effectively capture patient clinical responses to oncology therapy. European Journal of Cancer, 2016, 61, S203.	1.3	1
98	Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Medicine, 2016, 8, 62.	3.6	71
99	Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. Oncology and Therapy, 2016, 4, 1-16.	1.0	2
100	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2016, 387, 1629-1637.	6.3	610
101	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. Expert Review of Clinical Pharmacology, 2016, 9, 501-512.	1.3	4
102	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology, 2016, 34, 786-793.	0.8	647
103	Extraskeletal Osteogenic Sarcoma. , 2016, , 327-334.		1
104	Gastrointestinal Stromal Tumors. , 2016, , 77-104.		1
105	Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T		2
106	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028â€"A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 11006-11006.	0.8	37
107	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2016, 34, 11016-11016.	0.8	15
108	Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.. Journal of Clinical Oncology, 2016, 34, 11032-11032.	0.8	3

#	Article	IF	Citations
109	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. Journal of Clinical Oncology, 2016, 34, 11037-11037.	0.8	5
110	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. Journal of Clinical Oncology, 2016, 34, 11061-11061.	0.8	5
111	Efficacy of sorafenib in patients with desmoid-type fibromatosis.. Journal of Clinical Oncology, 2016, 34, 11065-11065.	0.8	7
112	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. Journal of Clinical Oncology, 2016, 34, 3086-3086.	0.8	3
113	Leiomyosarcoma. , 2016, , 125-142.		1
114	Sarcomas More Common in Children. , 2016, , 243-274.		0
115	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor. , 2016, , 165-176.		0
116	Radiation-Induced Sarcoma. , 2016, , 275-281.		0
117	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis). , 2016, , 177-194.		0
118	Uncommon/Unique Sites. , 2016, , 343-351.		1
119	Solitary Fibrous Tumor/Hemangiopericytoma. , 2016, , 195-201.		0
120	Extraskeletal Myxoid Chondrosarcoma. , 2016, , 307-313.		0
121	Liposarcoma. , 2016, , 105-124.		0
122	Other Uterine Sarcomas. , 2016, , 315-326.		0
123	Reactive Lesions. , 2016, , 387-390.		0
124	General Description. , 2016, , 3-17.		2
125	Natural History: Importance of Size, Site, Histopathology. , 2016, , 19-40.		0
126	Desmoplastic Small Round Cell Tumor. , 2016, , 299-305.		0

#	Article	IF	Citations
127	General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy. , 2016, , 41-74.		0
128	Sustentacular Tumors of Lymph Tissue. , 2016, , 335-341.		0
129	Synovial Sarcoma. , 2016, , 153-163.		0
130	Clear Cell Sarcoma/Melanoma of Soft Parts. , 2016, , 291-297.		0
131	Alveolar Soft Part Sarcoma. , 2016, , 283-289.		1
132	Vascular Sarcomas. , 2016, , 221-236.		0
133	Visualzing toxicity: A single score to summarize toxicity in randomized clinical trials.. Journal of Clinical Oncology, 2016, 34, 6605-6605.	0.8	0
134	364 A summary score to assess toxicity of small molecule oral kinase inhibitors (SMOKIs) in randomized clinical trials (RCTs). European Journal of Cancer, 2015, 51, S75.	1.3	0
135	Chromosome 9p21 Amplification in HNSCC Is Associated With Increased Mortality Following Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, S144.	0.4	0
136	3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). European Journal of Cancer, 2015, 51, S689.	1.3	4
137	3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer, 2015, 51, S700.	1.3	0
138	Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning. Medical Science Educator, 2015, 25, 413-420.	0.7	6
139	1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer, 2015, 51, S194.	1.3	0
140	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors, 2015, 7, 86-88.	0.3	30
141	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Frontiers in Oncology, 2015, 5, 186.	1.3	34
142	Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma, 2015, 2015, 1-7.	0.7	49
143	Age-Stratified Risk of Unexpected Uterine Sarcoma Following Surgery for Presumed Benign Leiomyoma. Oncologist, 2015, 20, 433-439.	1.9	59
144	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. European Journal of Cancer, 2015, 51, 1611-1617.	1.3	63

#	Article	IF	Citations
145	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	1.9	26
146	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	1.3	23
147	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. Journal of Clinical Oncology, 2015, 33, 1849-1854.	0.8	41
148	Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. Clinical Sarcoma Research, 2015, 5, 21.	2.3	5
149	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European Journal of Cancer, 2015, 51, 2413-2422.	1.3	79
150	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 2015, 51, 210-217.	1.3	97
151	Sarcomas. Pediatric Clinics of North America, 2015, 62, 179-200.	0.9	65
152	A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).. Journal of Clinical Oncology, 2015, 33, 10503-10503.	0.8	15
153	The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data.. Journal of Clinical Oncology, 2015, 33, 10508-10508.	0.8	8
154	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2015, 33, 10514-10514.	0.8	3
155	Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.. Journal of Clinical Oncology, 2015, 33, 10537-10537.	0.8	4
156	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	0.8	3
157	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.. Journal of Clinical Oncology, 2015, 33, TPS10578-TPS10578.	0.8	12
158	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	0.8	22
159	Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).. Journal of Clinical Oncology, 2015, 33, 10561-10561.	0.8	0
160	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. Journal of Clinical Oncology, 2015, 33, TPS10577-TPS10577.	0.8	1
161	Abstract 5589: Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. , 2015, , .		0
162	Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon?. Sarcoma, 2014, 2014, 1-7.	0.7	13

#	Article	IF	Citations
163	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. Expert Opinion on Orphan Drugs, 2014, 2, 653-664.	0.5	0
164	A phase 2 trial of R1507, a monoclonal antibody to the insulinâ€like growth factorâ€1 receptor (IGFâ€1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer, 2014, 120, 2448-2456.	2.0	158
165	Malignant Peripheral Nerve Sheath Tumors. Oncologist, 2014, 19, 193-201.	1.9	258
166	Primary Angiosarcoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 528-534.	0.6	34
167	International expert opinion on patient-tailored management of soft tissue sarcomas. European Journal of Cancer, 2014, 50, 679-689.	1.3	40
168	Patientâ€derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	2.0	154
169	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	0.8	252
170	Sarcomas of Soft Tissue. , 2014, , 1753-1791.e10.		3
171	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.. Journal of Clinical Oncology, 2014, 32, 10508-10508.	0.8	12
172	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. Journal of Clinical Oncology, 2014, 32, 10520-10520.	0.8	14
173	Stress and empathy among internal medicine trainees on an inpatient hematology-oncology ward.. Journal of Clinical Oncology, 2014, 32, 231-231.	0.8	1
174	Management of Soft Tissue Sarcoma. , 2013, , .		38
175	Toward Better Soft Tissue Sarcoma Staging: Building on American Joint Committee on Cancer Staging Systems Versions 6 and 7. Annals of Surgical Oncology, 2013, 20, 3377-3383.	0.7	52
176	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Targeted Oncology, 2013, 8, 211-213.	1.7	47
177	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2013, 14, 371-382.	5.1	171
178	Advanced chondrosarcomas: role of chemotherapy and survival. Annals of Oncology, 2013, 24, 2916-2922.	0.6	184
179	General Description. , 2013, , 1-17.		0
180	Angiosarcomas and Other Sarcomas of Endothelial Origin. Hematology/Oncology Clinics of North America, 2013, 27, 975-988.	0.9	32

#	Article	IF	Citations
181	When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease. Rare Cancers and Therapy, 2013, 1, 21-27.	0.2	3
182	Treatment of advanced gastrointestinal stromal tumors in patients over 75Âyears old: clinical and pharmacological implications. Targeted Oncology, 2013, 8, 295-300.	1.7	13
183	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor. , 2013, , 149-160.		1
184	Synovial Sarcoma. , 2013, , 137-147.		0
185	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	6.3	1,144
186	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leukemia Research, 2013, 37, 790-794.	0.4	24
187	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Annals of Oncology, 2013, 24, 537-542.	0.6	39
188	Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Frontiers in Oncology, 2013, 3, 9.	1.3	7
189	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Annals of Oncology, 2013, 24, 1924-1930.	0.6	43
190	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. Annals of Surgery, 2013, 258, 422-429.	2.1	150
191	Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Annals of Oncology, 2013, 24, 252-257.	0.6	97
192	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma, 2013, 2013, 1-8.	0.7	151
193	Solitary Fibrous Tumor/Hemangiopericytoma. , 2013, , 179-184.		2
194	Adjuvant therapy for highâ€grade, uterusâ€limited leiomyosarcoma. Cancer, 2013, 119, 1555-1561.	2.0	150
195	Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. British Journal of Cancer, 2013, 109, 1717-1724.	2.9	55
196	Preliminary Results of High-Dose Single-Fraction Radiotherapy for the Management of Chordomas of the Spine and Sacrum. Neurosurgery, 2013, 73, 673-680.	0.6	77
197	Leiomyosarcoma. , 2013, , 113-127.		1
198	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST.. , 2013, , .		4

#	Article	IF	Citations
199	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. Journal of Clinical Oncology, 2013, 31, 10503-10503.	0.8	26
200	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. Journal of Clinical Oncology, 2013, 31, 10514-10514.	0.8	17
201	A model for multi-institutional, multidisciplinary sarcoma videoconferencing.. Journal of Clinical Oncology, 2013, 31, 10521-10521.	0.8	2
202	Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence.. Journal of Clinical Oncology, 2013, 31, 10538-10538.	0.8	1
203	Desmoplastic Small Round Cell Tumor. , 2013, , 275-280.		1
204	Alveolar Soft Part Sarcoma. , 2013, , 259-265.		0
205	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis). , 2013, , 161-177.		0
206	Gastrointestinal Stromal Tumors (GISTs). , 2013, , 67-91.		0
207	Sarcomas More Common in Children. , 2013, , 221-250.		1
208	Natural History: Importance of Size, Site, and Histopathology. , 2013, , 19-35.		2
209	Benign Soft Tissue Tumors. , 2013, , 339-354.		2
210	Other Uterine Sarcomas. , 2013, , 289-299.		0
211	Extraskeletal Myxoid Chondrosarcoma. , 2013, , 281-287.		0
212	Vascular Sarcomas. , 2013, , 201-213.		0
213	Mostly Benign/Rarely Metastasizing Soft Tissue Tumor. , 2013, , 329-337.		0
214	Clear Cell Sarcoma/Melanoma of Soft Parts. , 2013, , 267-273.		1
215	Radiation-Induced Sarcomas. , 2013, , 251-257.		0
216	Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma. , 2013, , 129-136.		1

#	Article	IF	Citations
217	General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy. , 2013, , 37-64.		2
218	Sustentacular Tumors of Lymph Tissue. , 2013, , 309-315.		0
219	Liposarcoma. , 2013, , 93-111.		0
220	Uterine Sarcomas in the Elderly. , 2013, , 319-348.		0
221	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. Journal of Clinical Oncology, 2013, 31, 10551-10551.	0.8	1
222	Linking kinases to adverse events through kinase inhibitors.. Journal of Clinical Oncology, 2013, 31, e13524-e13524.	0.8	0
223	Squamous Cell Carcinoma of the Oral Tongue in Two Patients Previously Exposed to Long-Term Pegylated Liposomal Doxorubicin. Oncologist, 2012, 17, 1594-1595.	1.9	11
224	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	0.6	44
225	Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Annals of Oncology, 2012, 23, 2205-2206.	0.6	24
226	Ifosfamide in the Neoadjuvant Treatment of Osteogenic Sarcoma. Journal of Clinical Oncology, 2012, 30, 2033-2035.	0.8	16
227	Randomization and Statistical Power: Paramount in Trial Reproducibility (Even for Rare Cancers). Oncologist, 2012, 17, 1129-1132.	1.9	1
228	The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. Clinical Cancer Research, 2012, 18, 2638-2647.	3.2	85
229	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Annals of Oncology, 2012, 23, 1601-1607.	0.6	117
230	Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. Annals of Oncology, 2012, 23, 804-805.	0.6	6
231	New Therapeutic Targets in Soft Tissue Sarcoma. Advances in Anatomic Pathology, 2012, 19, 170-180.	2.4	45
232	How Do I Treat Patients with Metastatic Soft Tissue Sarcoma?. Oncology Times, 2012, 34, 12-14.	0.1	0
233	New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents. Clinical Cancer Research, 2012, 18, 5837-5844.	3.2	9
234	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. European Journal of Cancer, 2012, 48, 3036-3044.	1.3	129

#	Article	IF	Citations
235	Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery. Cancer Investigation, 2012, 30, 300-308.	0.6	13
236	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. European Journal of Cancer, 2012, 48, 547-563.	1.3	64
237	The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). Clinical Sarcoma Research, 2012, 2, 21.	2.3	5
238	Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial. Annals of Oncology, 2012, 23, xi20.	0.6	7
239	Targeting HDM2 (Human MDM2) in Sarcomas. Annals of Oncology, 2012, 23, ix54.	0.6	0
240	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. Annals of Oncology, 2012, 23, ix478-ix479.	0.6	3
241	Brain Metastases(BM) in Patients (PTS) with Soft Tissue and Bone Sarcoma (Sarcoma): A Retrospective Study of 107 Pts. Annals of Oncology, 2012, 23, ix489.	0.6	0
242	Targeted Therapy in Sarcoma: Should We Be Lumpers or Splitters?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 652-657.	1.8	2
243	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer, 2012, 118, 3330-3336.	2.0	118
244	Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas. Cancer, 2012, 118, 5878-5887.	2.0	103
245	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Investigational New Drugs, 2012, 30, 1193-1202.	1.2	71
246	Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence. Journal of the American College of Surgeons, 2012, 215, 53-59.	0.2	141
247	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology, 2012, 19, 1551-1559.	0.7	57
248	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes and Cancer, 2012, 51, 186-195.	1.5	17
249	High prevalence of CIC fusion with doubleâ€homeobox (DUX4) transcription factors in EWSR1â€negative undifferentiated small blue round cell sarcomas. Genes Chromosomes and Cancer, 2012, 51, 207-218.	1.5	307
250	The miRâ€17â€92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes and Cancer, 2012, 51, 569-578.	1.5	96
251	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	2.0	222
252	A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2012, 30, 10003-10003.	0.8	6

#	Article	IF	Citations
253	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. Journal of Clinical Oncology, 2012, 30, 10021-10021.	0.8	1
254	AÂphase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. Journal of Clinical Oncology, 2012, 30, e13600-e13600.	0.8	20
255	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	2
256	Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.. Journal of Clinical Oncology, 2012, 30, TPS10103-TPS10103.	0.8	1
257	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	11
258	Genome-wide analysis and characterization of an online sarcoma cohort.. Journal of Clinical Oncology, 2012, 30, 10097-10097.	0.8	0
259	Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors.. Journal of Clinical Oncology, 2012, 30, 10022-10022.	0.8	0
260	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. Journal of Clinical Oncology, 2012, 30, 10001-10001.	0.8	0
261	Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.. Journal of Clinical Oncology, 2012, 30, 10013-10013.	0.8	0
262	Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival.. Journal of Clinical Oncology, 2012, 30, 10057-10057.	0.8	0
263	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. European Journal of Cancer, 2011, 47, 1006-1012.	1.3	88
264	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1004-1012.	5.1	847
265	Eribulin in soft-tissue sarcomas. Lancet Oncology, The, 2011, 12, 988-989.	5.1	6
266	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	12.8	364
267	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Annals of Surgical Oncology, 2011, 18, 328-336.	0.7	88
268	Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2011, 67, 25-43.	1.1	71
269	Chemotherapy in clear cell sarcoma. Medical Oncology, 2011, 28, 859-863.	1.2	58
270	Consistent MYC and FLT4 gene amplification in radiationâ€induced angiosarcoma but not in other radiationâ€associated atypical vascular lesions. Genes Chromosomes and Cancer, 2011, 50, 25-33.	1.5	291

#	Article	IF	Citations
271	A novel WWTR1â€CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes and Cancer, 2011, 50, 644-653.	1.5	445
272	Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor Cixutumumab. Journal of Clinical Oncology, 2011, 29, e638-e640.	0.8	6
273	Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research, 2011, 17, 4082-4090.	3.2	237
274	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. Journal of Thoracic Oncology, 2011, 6, 942-946.	0.5	407
275	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. Journal of Clinical Oncology, 2011, 29, 4541-4547.	0.8	293
276	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. Journal of Clinical Oncology, 2011, 29, 10000-10000.	0.8	13
277	Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.. Journal of Clinical Oncology, 2011, 29, 10009-10009.	0.8	51
278	Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.. Journal of Clinical Oncology, 2011, 29, 10044-10044.	0.8	4
279	Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.. Journal of Clinical Oncology, 2011, 29, 10079-10079.	0.8	11
280	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2011, 29, 2501-2501.	0.8	101
281	Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. Journal of Clinical Oncology, 2011, 29, 3039-3039.	0.8	5
282	Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2011, 29, 4-4.	0.8	8
283	Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.. Journal of Clinical Oncology, 2011, 29, 10071-10071.	0.8	1
284	Comments regarding lung metastasis surgery for sarcoma. Oncology, 2011, 25, 1210-1.	0.4	0
285	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-1-S-41.	2.3	1,004
286	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 2044-2046.	0.5	73
287	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer, 2010, 116, 2258-2265.	2.0	163
288	Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevecâ„¢). Leukemia Research, 2010, 34, 827-829.	0.4	28

#	Article	IF	Citations
289	IGF2 overâ€expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. Journal of Pathology, 2010, 221, 300-307.	2.1	78
290	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.	13.7	279
291	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	9.4	642
292	Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine, 2010, 363, 1727-1733.	13.9	769
293	Benign Mesenchymal Stromal Cells in Human Sarcomas. Clinical Cancer Research, 2010, 16, 5630-5640.	3.2	20
294	Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clinical Cancer Research, 2010, 16, 4884-4891.	3.2	213
295	Anaplastic Lymphoma Kinase Inhibition in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2010, 363, 1693-1703.	13.9	4,141
296	Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer. Journal of Clinical Oncology, 2010, 28, 4985-4995.	0.8	190
297	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology, 2010, 28, 835-840.	0.8	362
298	A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).. Journal of Clinical Oncology, 2010, 28, 10004-10004.	0.8	16
299	Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.. Journal of Clinical Oncology, 2010, 28, 10006-10006.	0.8	52
300	Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).. Journal of Clinical Oncology, 2010, 28, 10013-10013.	0.8	5
301	Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.. Journal of Clinical Oncology, 2010, 28, 10021-10021.	0.8	8
302	Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).. Journal of Clinical Oncology, 2010, 28, 10029-10029.	0.8	2
303	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.. Journal of Clinical Oncology, 2010, 28, 2596-2596.	0.8	30
304	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2010, 28, 3-3.	0.8	98
305	Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor. Archives of Pathology and Laboratory Medicine, 2010, 134, 165-170.	1.2	57
306	Abstract LB-62: Direct visualization of circulating sarcoma cells by whole-blood fluorescence in-situ hybridization. , 2010, , .		0

#	Article	IF	Citations
307	Systemic therapy in clear cell sarcoma.. Journal of Clinical Oncology, 2010, 28, 10098-10098.	0.8	1
308	Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization.. Journal of Clinical Oncology, 2010, 28, 10637-10637.	0.8	0
309	Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST). Blood, 2010, 116, 2276-2276.	0.6	0
310	Role of interleukin 12 and costimulators in T cell anergy in vivo. Journal of Experimental Medicine, 2009, 206, 1207-1207.	4.2	13
311	KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors. Cancer Research, 2009, 69, 7175-7179.	0.4	247
312	Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis. Sarcoma, 2009, 2009, 1-5.	0.7	8
313	Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. Journal of Clinical Oncology, 2009, 27, 3148-3153.	0.8	210
314	A case of high-risk penile epithelioid hemangioendothelioma. Nature Reviews Urology, 2009, 6, 223-227.	1.9	11
315	Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. Journal of Clinical Oncology, 2009, 27, 3154-3160.	0.8	295
316	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clinical Cancer Research, 2009, 15, 5902-5909.	3.2	133
317	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	3.2	86
318	Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas. Journal of Clinical Oncology, 2009, 27, 3133-3140.	0.8	522
319	Introduction: The 2008 European Society for Medical Oncology International Symposium on Sarcomas and Gastrointestinal Stromal Tumors. Seminars in Oncology, 2009, 36, 289.	0.8	0
320	Sarcomas With Spindle Cell Morphology. Seminars in Oncology, 2009, 36, 324-337.	0.8	28
321	Other Targetable Sarcomas. Seminars in Oncology, 2009, 36, 358-371.	0.8	12
322	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. Cancer Investigation, 2009, 27, 402-406.	0.6	1
323	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	5.1	430
324	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 373, 1097-1104.	6.3	1,233

#	Article	IF	Citations
325	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. European Journal of Cancer, Supplement, 2009, 7, 590.	2.2	2
326	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. European Journal of Cancer, Supplement, 2009, 7, 590-591.	2.2	3
327	GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. Current Cancer Therapy Reviews, 2009, 5, 100-104.	0.2	1
328	A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. Journal of Clinical Oncology, 2009, 27, 10503-10503.	0.8	20
329	Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. Journal of Clinical Oncology, 2009, 27, 3509-3509.	0.8	118
330	Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. Journal of Clinical Oncology, 2009, 27, e13510-e13510.	0.8	8
331	Abstract C250: The pericyte as a novel stromal element and therapeutic target in sarcoma. , 2009, , .		0
332	Pediatric sarcomas occurring in adults. Journal of Surgical Oncology, 2008, 97, 360-368.	0.8	32
333	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112, 608-615.	2.0	437
334	Extraskeletal myxoid chondrosarcoma. Cancer, 2008, 113, 3364-3371.	2.0	272
335	Novel V600E BRAF mutations in imatinibâ€naive and imatinibâ€resistant gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2008, 47, 853-859.	1.5	329
336	Why Do Patients with Low-Grade Soft Tissue Sarcoma Die?. Annals of Surgical Oncology, 2008, 15, 3550-3560.	0.7	64
337	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. American Journal of Pathology, 2008, 172, 1069-1080.	1.9	65
338	Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2008, 26, 5352-5359.	0.8	693
339	Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii35-ii38.	0.6	138
340	A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib. Journal of the National Cancer Institute, 2008, 100, 282-284.	3.0	174
341	A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle, 2008, 7, 720-724.	1.3	21
342	Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii89-ii93.	0.6	101

#	Article	IF	Citations
343	A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients. Clinical Cancer Research, 2008, 14, 8191-8197.	3.2	160
344	Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 2008, 26, 626-632.	0.8	951
345	A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. Clinical Cancer Research, 2008, 14, 6704-6711.	3.2	59
346	Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2008, 14, 3204-3215.	3.2	233
347	DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays. Cancer Informatics, 2008, 6, CIN.S387.	0.9	3
348	EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. Sarcoma, 2008, 2008, 1-6.	0.7	36
349	Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. Journal of Clinical Oncology, 2008, 26, 10502-10502.	0.8	64
350	Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. Journal of Clinical Oncology, 2008, 26, 10529-10529.	0.8	2
351	Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. Journal of Clinical Oncology, 2008, 26, 10531-10531.	0.8	15
352	Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. Journal of Clinical Oncology, 2008, 26, 10533-10533.	0.8	13
353	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	3.2	118
354	Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 2643-2650.	3.2	202
355	Evidence-Based Recommendations for Local Therapy for Soft Tissue Sarcomas. Journal of Clinical Oncology, 2007, 25, 1003-1008.	0.8	156
356	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. Cancer Research, 2007, 67, 6626-6636.	0.4	217
357	Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	3.2	144
358	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery, 2007, 245, 347-352.	2.1	273
359	Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma. Annals of Surgery, 2007, 246, 105-113.	2.1	187
360	Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future. Oncologist, 2007, 12, 999-1006.	1.9	89

#	Article	IF	Citations
361	Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncology, The, 2007, 8, 513-524.	5.1	133
362	CYP3A4/5 and pharmacogenetics in patients with sarcoma â€“ Authors' reply. Lancet Oncology, The, 2007, 8, 668-669.	5.1	0
363	Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leukemia and Lymphoma, 2007, 48, 2071-2074.	0.6	7
364	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. Journal of Clinical Oncology, 2007, 25, 2755-2763.	0.8	655
365	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2007, 14, 134-142.	0.7	104
366	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic softâ€tissue sarcoma of the extremity. Cancer, 2007, 110, 2050-2060.	2.0	50
367	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	15.2	275
368	A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma. Digestive Diseases and Sciences, 2007, 52, 1964-1972.	1.1	89
369	Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports, 2007, 9, 165-169.	1.8	12
370	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, 117, 3248-3257.	3.9	167
371	Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study) Tj ETQq1 1 0.784314 rgBT /Over	0.8	16
372	Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). Journal of Clinical Oncology, 2007, 25, 10061-10061.	0.8	3
373	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)â€"Update of the NCCN Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, S-1-S-29.	2.3	360
374	Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors. Journal of Clinical Oncology, 2007, 25, 3533-3533.	0.8	1
375	Gastrointestinal Stromal Tumors (GIST) and Their Management. Gastrointestinal Cancer Research: GCR, 2007, 1, S81-4.	0.8	1
376	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5 Suppl 2, S1-29; quiz S30.	2.3	201
377	Management Dilemmas Due to a Paratracheal Follicular Dendritic Cell Tumor. Annals of Thoracic Surgery, 2006, 82, 1898-1900.	0.7	8
378	A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas. Sarcoma, 2006, 2006, 1-4.	0.7	32

#	Article	IF	Citations
379	Future directions for immunotherapeutic intervention against sarcomas. Current Opinion in Oncology, 2006, 18, 363-368.	1.1	17
380	The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects: Fig. 1.. Clinical Cancer Research, 2006, 12, 6203-6204.	3.2	29
381	Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. New England Journal of Medicine, 2006, 354, 2006-2013.	13.9	289
382	Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Journal of Clinical Oncology, 2006, 24, 9502-9502.	0.8	62
383	Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. Journal of Clinical Oncology, 2006, 24, 9503-9503.	0.8	14
384	A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. Journal of Clinical Oncology, 2006, 24, 9507-9507.	0.8	2
385	A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Journal of Clinical Oncology, 2006, 24, 9514-9514.	0.8	11
386	A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology, 2006, 24, 9515-9515.	0.8	11
387	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). Journal of Clinical Oncology, 2006, 24, 9522-9522.	0.8	20
388	A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. Journal of Clinical Oncology, 2006, 24, 9523-9523.	0.8	1
389	Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect. Journal of Clinical Oncology, 2006, 24, 9526-9526.	0.8	1
390	De Novo Osteogenic Sarcoma in Patients Older Than Forty. Clinical Orthopaedics and Related Research, 2005, &NA;, 110-115.	0.7	34
391	Gastrointestinal Stromal Tumors in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2005, 27, 179-187.	0.3	239
392	A 14-Year Retrospective Review of Angiosarcoma. Cancer Journal (Sudbury, Mass), 2005, 11, 241-247.	1.0	350
393	The Influence of Older Age on Outcome in Soft Tissue Sarcoma of the Extremity. International Journal of Radiation Oncology Biology Physics, 2005, 63, S51.	0.4	0
394	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer, 2005, 103, 1431-1438.	2.0	78
395	Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study. Journal of Clinical Oncology, 2005, 23, 5484-5492.	0.8	173
396	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research, 2005, 11, 4182-4190.	3.2	768

#	Article	IF	Citations
397	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2005, 23, 1875-1884.	0.8	113
398	Problems in Colon Cancer and a Child With Renal Lymphoma. Journal of Clinical Oncology, 2005, 23, 5255-5256.	0.8	6
399	Bluish Papule in a Middle-aged Manâ€"Quiz Case. Archives of Dermatology, 2005, 141, 1595-600.	1.7	1
400	Mechanisms of Sarcomagenesis. Hematology/Oncology Clinics of North America, 2005, 19, 427-449.	0.9	19
401	Sarcomas. Hematology/Oncology Clinics of North America, 2005, 19, xi-xii.	0.9	0
402	Consensus meeting for the management of gastrointestinal stromal tumorsâ€¨ Report of the GIST Consensus Conference of 20â€“21 March 2004, under the auspices of ESMO. Annals of Oncology, 2005, 16, 566-578.	0.6	628
403	Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas. Journal of Clinical Oncology, 2005, 23, 7135-7142.	0.8	244
404	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2005, 23, 9011-9011.	0.8	78
405	Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2005, 23, 9032-9032.	0.8	4
406	Fighting Cancer Through the Study of Sarcomas. American Scientist, 2005, 93, 414.	0.1	2
407	Fighting Cancer Through the Study of Sarcomas. American Scientist, 2005, 93, 414.	0.1	0
408	Molecular profiling of liposarcoma subtypes. Journal of Clinical Oncology, 2005, 23, 9016-9016.	0.8	0
409	Role of chemotherapy in patients with soft tissue sarcomas. Expert Review of Anticancer Therapy, 2004, 4, 229-236.	1.1	21
410	Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology, 2004, 22, 1480-1490.	0.8	280
411	Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia. Clinical Cancer Research, 2004, 10, 1250-1254.	3.2	97
412	Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. Journal of Clinical Oncology, 2004, 22, 4567-4574.	0.8	149
413	Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Annals of Oncology, 2004, 15, 1667-1672.	0.6	184
414	Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Current Treatment Options in Gastroenterology, 2004, 7, 13-17.	0.3	24

#	Article	IF	Citations
415	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. Clinical Cancer Research, 2004, 10, 3282-3290.	3.2	194
416	The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma. Annals of Surgery, 2004, 240, 686-697.	2.1	132
417	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2004, 22, 3001-3001.	0.8	38
418	Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. Journal of Clinical Oncology, 2004, 22, 9001-9001.	0.8	8
419	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. Journal of Clinical Oncology, 2004, 22, 9013-9013.	0.8	4
420	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. Journal of Clinical Oncology, 2004, 22, 9017-9017.	0.8	4
421	Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial. Journal of Clinical Oncology, 2004, 22, 9010-9010.	0.8	6
422	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. Journal of Clinical Oncology, 2004, 22, 9013-9013.	0.8	5
423	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. Journal of Clinical Oncology, 2004, 22, 9017-9017.	0.8	2
424	NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 1, S-1-26; quiz 27-30.	2.3	45
425	Immunity against soft-tissue sarcomas. Current Oncology Reports, 2003, 5, 282-287.	1.8	11
426	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer, 2003, 98, 832-840.	2.0	97
427	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. American Journal of Pathology, 2003, 163, 691-700.	1.9	207
428	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	3.3	179
429	Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma. Current Opinion in Orthopaedics, 2003, 14, 419-428.	0.3	9
430	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. Current Problems in Surgery, 2003, 40, 144-193.	0.6	23
431	The intricate interplay among body weight, stress, and the immune response to friend or foe. Journal of Clinical Investigation, 2003, 111, 183-185.	3.9	34
432	Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial. Journal of Clinical Oncology, 2002, 20, 2824-2831.	0.8	681

#	Article	IF	Citations
433	Multidisciplinary Management of Soft-Tissue Sarcomas. Cancer Investigation, 2002, 20, 818-824.	0.6	5
434	A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors. Oncologist, 2002, 7, 531-538.	1.9	54
435	Sarcomas of Soft Tissue. , 2002, , 197-203.		0
436	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International Journal of Cancer, 2002, 100, 623-626.	2.3	262
437	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemotherapy and Pharmacology, 2002, 50, 309-319.	1.1	61
438	Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Current Opinion in Oncology, 2001, 13, 270-274.	1.1	25
439	Cascades of transcriptional induction during human lymphocyte activation. European Journal of Cell Biology, 2001, 80, 321-328.	1.6	35
440	Sarcoma. Oncologist, 2001, 6, 333-337.	1.9	3
441	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Medicine, 2000, 6, 991-997.	15.2	1,945
442	Role of Interleukin 12 and Costimulators in T Cell Anergy In Vivo. Journal of Experimental Medicine, 1997, 186, 1119-1128.	4.2	84
443	Structureâ^'Activity Relationships ofN-Hydroxyurea 5-Lipoxygenase Inhibitors. Journal of Medicinal Chemistry, 1997, 40, 1955-1968.	2.9	40
444	Tumor-specific cell surface expression of the -KDEL containing endoplasmic reticular heat shock protein gp96. , 1996, 69, 340-349.		159
445	O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1547-1552.	1.0	12
446	Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. Somatic Cell and Molecular Genetics, 1993, 19, 73-81.	0.7	30
447	Stress-Induced Proteins in Immune Response to Cancer. Current Topics in Microbiology and Immunology, 1991, 167, 109-123.	0.7	141
448	Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 5658-5662.	3.3	134
449	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. Journal of Medicinal Chemistry, 1990, 33, 1582-1590.	2.9	26
450	New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. Journal of Medicinal Chemistry, 1990, 33, 534-542.	2.9	99

#	Article	IF	Citations
451	Evaluation of the rate constant for the reaction OH+H2CO: Application of modeling and sensitivity analysis techniques for determination of the product branching ratio. Journal of Chemical Physics, 1989, 91, 4088-4097.	1.2	41
452	An iterative synthesis of radiolabelled polyethylene glycol oligomers. Journal of Labelled Compounds and Radiopharmaceuticals, 1989, 27, 1437-1450.	0.5	4
453	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. Biochemistry, 1988, 27, 1111-1116.	1.2	9
454	Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. Journal of Medicinal Chemistry, 1987, 30, 2137-2144.	2.9	38
455	The enantio- and diastereoselective synthesis of the first phospho-statine derivative. Tetrahedron Letters, 1986, 27, 2337-2340.	0.7	32
456	Lyman-.alpha. photometry: curve of growth determination, comparison to theoretical oscillator strength, and line absorption calculations at high temperature. The Journal of Physical Chemistry, 1985, 89, 4815-4821.	2.9	31
457	MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS. , 0, , 1070-1082.		1